A NOVEL CHOLESTEROL METABOLITE, 5-CHOLESTEN, 3ß-25-DIOL, DISULFATE (25HCDS) FOR THERAPY OF METABOLIC DISORDERS, HYPERLIPIDEMIA, DIABETES, FATTY LIVER DISEASES AND ATHEROSCLEROSIS.

摘要

5-cholesten, 3ß, 25-diol, disulfate (25HCDS) has been found to be an authentic PPARÏ’ agonist and LXR antagonist, and is used for the therapy of lipid disorders and inflammatory diseases, including without limitation fatty liver, inflammatory bowel, and atherosclerotic diseases.